Edition:
United States

Boule Diagnostics AB (BOUL.ST)

BOUL.ST on Stockholm Stock Exchange

312.00SEK
11:29am EST
Change (% chg)

-12.00kr (-3.70%)
Prev Close
324.00kr
Open
318.00kr
Day's High
323.50kr
Day's Low
307.50kr
Volume
33,432
Avg. Vol
26,429
52-wk High
325.00kr
52-wk Low
62.50kr

BOUL.ST

Chart for BOUL.ST

About

Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that... (more)
No analyst recommendations are available for BOUL.ST.

Overall

Beta: 0.98
Market Cap(Mil.): kr1,525.11
Shares Outstanding(Mil.): 4.71
Dividend: 0.60
Yield (%): 0.19

Financials

  BOUL.ST Industry Sector
P/E (TTM): 43.17 62.10 30.76
EPS (TTM): 7.51 -- --
ROI: 15.93 7.17 14.82
ROE: 17.45 10.71 16.24

BRIEF-Tredje AP-fonden buys 7.6 pct stake in Boule Diagnostics

* Says Tredje AP-fonden buys 358,068 shares in Boule Diagnostics AB corresponding to 7.6 percent stake

5:30am EST

BRIEF-Boule Diagnostics names Fredrik Dalborg new CEO

* Dalborg to replace Ernst Westman, who will leave CEO post and company in Q1 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 10 2017

BRIEF-Boule Diagnostics Q3 operating profit up at SEK 24.8 mln

* Q3 net sales 108.5 million Swedish crowns ($12 million)versus 88.8 million crowns year ago

Nov 09 2016

BRIEF-Boule Diagnostics wins assignment from Red Cross in Kenya

* Wins assignment from Red Cross in Kenya Source text for Eikon:

Oct 17 2016

BRIEF-Boule Diagnostics wins contract in USA

* Says has signed deal with Novant Health Systems in United States, as primary vendor for three part differential hematology systems

Aug 26 2016

BRIEF-Boule Diagnostics Q2 operating profit up at SEK 12.6 million

* Q2 net sales 102.0 million Swedish crowns ($11.9 million) versus 78.9 million crowns year ago

Aug 01 2016

Earnings vs. Estimates